Compugen Announces US Patent Allowance for Drug Candidate Recently Presented at 2013 American Thoracic Society Meeting
15 Julio 2013 - 6:00AM
Business Wire
Compugen Ltd. (NASDAQ: CGEN) announced today that the company
has received an Issue Notification from the U.S. Patent and
Trademark Office for a patent application covering the company's
drug candidate CGEN-25009. CGEN-25009 is intended for the treatment
of idiopathic pulmonary fibrosis, a devastating disease with no
current effective treatment. This novel peptide agonist of the
relaxin receptor was the subject of a recent presentation by Dr.
Daniel Kass, from the University of Pittsburgh (“Pitt”), at the
2013 American Thoracic Society Conference.
In his presentation, Dr. Kass, Assistant Professor of Medicine
at Pitt and Assistant Director for Novel Therapeutics and
Translational Research at The Dorothy P. and Richard P. Simmons
Center for Interstitial Lung Disease at the University of
Pittsburgh Medical Center, presented experimental data
demonstrating that CGEN-25009 protects mice from bleomycin-induced
pulmonary fibrosis. In this model, CGEN-25009 treatment reduced
lung fibrosis as determined by collagen deposition in both
preventive and therapeutic administration regimens.
As previously announced by Compugen, the Pulmonary Fibrosis
Foundation provided a grant to scientists at Pitt to independently
evaluate the therapeutic potential of CGEN-25009 for the treatment
of idiopathic pulmonary fibrosis (IPF), a life-threatening disease
affecting an estimated more than five million people worldwide.
Dr. Anat Cohen-Dayag, president and CEO of Compugen, stated, “We
are very pleased with the CGEN-25009 results presented by Dr. Kass,
and we hope that this therapeutic peptide candidate will eventually
improve the lives of many patients.”
Dr. Cohen-Dayag added, “The new US patent, which will be issued
on July 23, 2013 as US Patent No. 8,492,329, as well as previous
patents granted or allowed for CGEN-25009 in the European Union and
Australia, provide composition of matter protection for this novel
molecule. These patents and allowances underscore the company’s
strategy to obtain broad protection for its discoveries and
represent an important milestone in the development of this
attractive product candidate.”
About CompugenCompugen is a leading drug discovery
company focused on therapeutic proteins and monoclonal antibodies
to address important unmet needs in the fields of immunology and
oncology. The Company utilizes a broad and continuously growing
integrated infrastructure of proprietary scientific understandings
and predictive platforms, algorithms, machine learning systems and
other computational biology capabilities for the in
silico (by computer) prediction and selection of product
candidates, which are then advanced in its Pipeline Program. The
Company's business model includes collaborations covering the
further development and commercialization of selected product
candidates from its Pipeline Program and various forms of research
and discovery agreements, in both cases providing Compugen with
potential milestone payments and royalties on product sales or
other forms of revenue sharing. In 2012, Compugen established
operations in California for the development of oncology and
immunology monoclonal antibody therapeutic candidates against
Compugen drug targets. For additional information, please visit
Compugen's corporate website at www.cgen.com.
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995. These statements, which include statements related to the
potential of CGEN-25009 as an attractive development candidate for
IPF, include words such as “may,” “expects,” “anticipates,”
“potential,” “believes,” and “intends,” and describe opinions about
future events. These forward-looking statements involve known and
unknown risks and uncertainties that may cause the actual results,
performance or achievements of Compugen to be materially different
from any future results, performance or achievements expressed or
implied by such forward-looking statements. Some of these risks and
other factors are discussed in the "Risk Factors" section of
Compugen’s Annual Report on Form 20-F for the year ended December
31, 2012 as filed with the Securities and Exchange Commission. In
addition, any forward-looking statements represent Compugen’s views
only as of the date of this release and should not be relied upon
as representing its views as of any subsequent date. Compugen does
not assume any obligation to update any forward-looking statements
unless required by law.
Compugen (NASDAQ:CGEN)
Gráfica de Acción Histórica
De Sep 2024 a Oct 2024
Compugen (NASDAQ:CGEN)
Gráfica de Acción Histórica
De Oct 2023 a Oct 2024
